Profusa (NASDAQ:PFSA) Stock Rating Upgraded by Wall Street Zen

Profusa (NASDAQ:PFSA) was upgraded by analysts at Wall Street Zen to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings downgraded shares of Profusa from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Profusa has an average rating of “Sell”.

Profusa Stock Performance

Shares of NASDAQ:PFSA opened at $5.46 on Friday. The company has a market capitalization of $3.33 million, a price-to-earnings ratio of -0.00 and a beta of 0.52. Profusa has a 12-month low of $3.22 and a 12-month high of $5,190.00. The business has a 50-day moving average price of $9.48 and a 200 day moving average price of $70.44.

Profusa (NASDAQ:PFSA) last posted its earnings results on Wednesday, August 19th. The company reported ($151.80) EPS for the quarter.

Insider Buying and Selling at Profusa

In related news, major shareholder Financial Lp Hrt sold 10,602 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $3.56, for a total value of $37,743.12. Following the sale, the insider owned 18,549 shares in the company, valued at approximately $66,034.44. The trade was a 36.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 4,308 shares of company stock valued at $16,594 over the last ninety days. Insiders own 0.76% of the company’s stock.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.